Research programme: human genomics - CHUQ/SignalGene

Drug Profile

Research programme: human genomics - CHUQ/SignalGene

Alternative Names: Breast cancer research programme - SignalGene/CHUQ; human genomics research programme - SignalGene/CHUQ; Osteoporosis research programme - Signal Gene/CHUQ

Latest Information Update: 02 Dec 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centre Hospitalier Universitaire de Quebec; SignalGene [CEASED]
  • Developer Centre Hospitalier Universitaire de Quebec
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Osteoporosis; Psoriasis

Most Recent Events

  • 15 May 2002 Discontinued - Preclinical for Breast cancer in Canada (unspecified route)
  • 15 May 2002 Discontinued - Preclinical for Osteoporosis in Canada (unspecified route)
  • 09 May 2002 Discontinued - Preclinical for Psoriasis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top